Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stake in Merck & Co., Inc. $MRK

Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 7.0% in the 2nd quarter, Holdings Channel reports. The firm owned 6,184,340 shares of the company’s stock after purchasing an additional 402,011 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Merck & Co., Inc. were worth $794,577,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $25,000. Abound Financial LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth about $26,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $26,000. High Note Wealth LLC grew its position in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. during the fourth quarter worth about $31,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Merck & Co., Inc.

In other news, EVP David Michael Williams sold 52,847 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 228,238 shares of company stock worth $29,977,783. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Trading Up 3.9%

NYSE MRK opened at $156.54 on Wednesday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm’s fifty day moving average price is $129.64 and its 200 day moving average price is $121.80. The company has a market capitalization of $386.22 billion, a price-to-earnings ratio of 125.23, a price-to-earnings-growth ratio of 6.32 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the previous year, the company earned $2.13 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MRK. Cantor Fitzgerald reissued a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Wells Fargo & Company increased their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Barclays lifted their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. The Goldman Sachs Group raised their price objective on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a report on Friday, August 21st. Finally, CICC Research assumed coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price target on the stock. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $147.60.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive topline INTerpath-001 results strengthened expectations that the vaccine could extend KEYTRUDA’s growth runway and create a potentially important new oncology franchise. Merck Surges on a Melanoma Win
• Positive Sentiment: Analysts raised their valuation expectations: Wolfe Research increased its price target to $180 and assigned an “outperform” rating, while Argus raised its target to $170 and reiterated a “buy” rating. Wolfe Research Price Target
• Positive Sentiment: Investors are also anticipating a concentrated series of regulatory decisions and clinical readouts this fall, which could produce additional upside if Merck’s pipeline delivers. What Would It Take to Get MRK Stock to $200?
• Neutral Sentiment: The cancer-vaccine opportunity remains early. The available evidence is limited, and potential barriers include manufacturing complexity, cost, patient selection, and the need for regulatory review and broader clinical validation. How the Merck/Moderna Cancer Vaccine Works
• Negative Sentiment: After the recent rally, MRK is trading near or above several analysts’ prior targets, leaving less room for disappointment and making future gains increasingly dependent on successful trial results, FDA decisions, and evidence that the post-KEYTRUDA growth strategy can scale.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.